<p>Lp-PLA₂ Selective Inhibitor (Darapladib) Effect In Lowering The Expression Level Of IL-1B And IL-6 In The Renal At Type 2 Diabetes Mellitus</p>

Abstract

PurposeThe aim of this study is to prove that type 2 diabetes mellitus can induce increasing inflammation marker in renal and that the provision of darapladib as Lp-LA2 Inhibitor agents can inhibit inflammation that were measured from the expression of IL-1B and IL-6- type cytokine in renal. This study also discusses the correlation between IL-1B and IL-6- type cytokine expression in renal.MethodsThirty Sprague-Dawley (SD) rats were divided into three main groups; those are negative control group (NC), Type 2 Diabetes Mellitus group (T2DM) given high fat diet (HFD) with streptozotocin intraperitoneal injection (35mg/kg BW) and diabetes mellitus + darapladib group (DM + DP). Each group was treated within two serial treatment time: 8 weeks and 16 weeks. Expressions of IL-1B and IL-6- type cytokine in renal were the markers that we measured by immunofluorosense method.ResultsThe administration of darapladib can significantly decrease the expression of IL-1B- type cytokine (p ANOVA = 0.029, p < 0.005) measured in rats’ renal both at weeks 8 and 16 in the T2DM group. The Expression of IL-6- type cytokine also showed a significant difference after treated with darapladib both at weeks 8 and 16 in T2DM group with p-value of ANOVA = 0.033, p < 0.005. The Pearson correlation showed a strong correlation (linear regression value was r2 = 0.743).ConclusionOur results show that atherosclerosis caused by inflammation in renal T2DM SD rats could be inhibited by the administration of darapladib.

The changes of Lp-PLA2 in patients with gestational diabetes and its clinical significance

“…[11] Recently, Lp-PLA2 has been found to be abnormally up-regulated in type 2 diabetes, and its inhibitors have been used to treat the complications of type 2 diabetes with remarkable effects. [12][13][14][15][16] Since GDM is a special type of diabetes with similar pathophysiological characteristics as type 2 diabetes, we speculate that the inflammatory marker Lp-PLA2 may also be associated with GDM to some extent.…”

FAM3D inhibits gluconeogenesis in high glucose environment via DUSP1/ZFP36/SIK1 axis

“…However, its function in diabetes needs further exploration. In animal models of diabetes and T2DM patients, macrophages can be observed to infiltrate tissues, and promote the expression of TNF‐α, IL‐6, and IL‐1β 2,8,9 . The Zinc finger protein 36 (ZFP36) is an RNA‐binding protein that can be rapidly induced by a variety of pro‐inflammatory stimuli such as IL‐1β 10,11 .…”

“…In animal models of diabetes and T2DM patients, macrophages can be observed to infiltrate tissues, and promote the expression of TNF-α, IL-6, and IL-1β. 2,8,9 The Zinc finger protein 36 (ZFP36) is an RNA-binding protein that can be rapidly induced by a variety of pro-inflammatory stimuli such as IL-1β. 10,11 It has been reported in the literature that the expression of ZFP36 was increased under the stimulation of IL-1β, and overexpression of DUSP1 can down-regulate the expression of ZFP36.…”